RBC Ups Siemens Healthineers Price Target After Accela Launch

12:02 PM EDT, 10/16/2026 (MT Newswires) -- RBC Capital Markets raised its price target for Siemens Healthineers (SHL.F), noting that the German medical technology company's recent rollout of its Accela radiation therapy delivery system supports its upside scenario. "Siemens Healthineers' Varian Accela launch at ASTRO confirms key clinical capabilities identified in our pre-announcement note, while early investigational data suggests improved throughput and expansion of patient eligibility for radiotherapy. This is supported by company commentary around demand and premium positioning of the platform. We upgrade our FY30E Precision Therapy sales in line with our previously published 'upside' scenario," analysts said Friday. The research firm also identified several near-term catalysts that could support a more bullish scenario for the company, including the expected CE mark approval in November 2026 and further clinical data, as well as US regulatory approval in early 2027. Taking these into account, RBC lifted the outperform-rated stock's price target to 48 euros from 45 euros. Earnings forecasts for fiscal years 2027 through 2030 were also revised.